Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Debt to Equity (2021)

ARS Pharmaceuticals' Debt to Equity history spans 1 years, with the latest figure at -$0.16 for Q4 2021.

  • For Q4 2021, Debt to Equity changed N/A year-over-year to -$0.16; the TTM value through Dec 2021 reached -$0.16, changed N/A, while the annual FY2021 figure was -$0.16, N/A changed from the prior year.
  • Debt to Equity for Q4 2021 was -$0.16 at ARS Pharmaceuticals, down from $0.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.0 in Q1 2021 and bottomed at -$0.16 in Q4 2021.